Skip to main content
Clinical Trials/NCT03946930
NCT03946930
Recruiting
N/A

A Cohort Study of Cognitive Decline in Alzheimer Disease

Chinese University of Hong Kong1 site in 1 country500 target enrollmentDecember 13, 2018

Overview

Phase
N/A
Intervention
Not specified
Conditions
Alzheimer Disease
Sponsor
Chinese University of Hong Kong
Enrollment
500
Locations
1
Primary Endpoint
Alzheimer's Disease Assessment Scale-cognitive subscale ADAS-COG
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

There is lack of information on the risk factors of accelerated cognitive decline in older people with Alzheimer disease (AD). The extent of neurodegeneration and white matter disease has been reported to be important factors. In addition there may be biomarkers e.g. inflammatory cytokines that can contribute to cognitive decline. The impact of care arrangement and physical activity may also be important. Insulin signaling is impaired in Alzheimer disease (AD).

We therefore propose to perform a cohort study of older people with AD. This will be based on an on-going AD registry which was designed to identify genetic biomarkers for AD. Detailed neurocognitive tests and lifestyle information are available. In addition, volumetric MRI brain scans were performed in all AD subjects. The hypothesis is that MRI brain volumes, serum biomarkers, physical activity, physical functioning are independently associated with cognitive decline in older people with AD. The objective is to identify risk factors of accelerated cognitive decline so that preventive measures can be designed to delay dependency in AD.

Registry
clinicaltrials.gov
Start Date
December 13, 2018
End Date
December 31, 2027
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Timothy Kwok

Professor

Chinese University of Hong Kong

Eligibility Criteria

Inclusion Criteria

  • Sufficient Cantonese competency for cognitive test
  • Clinical diagnosis of AD
  • FAST test staging 3-5

Exclusion Criteria

  • Subjects who refuse blood taking procedure
  • No reliable family caregiver informant (person contact at least once a month)

Outcomes

Primary Outcomes

Alzheimer's Disease Assessment Scale-cognitive subscale ADAS-COG

Time Frame: 24-Months

Cognitive assessment for dementia

Study Sites (1)

Loading locations...

Similar Trials